Kotak Healthcare Fund
The scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors.
Growthvine rating: 1/5 — ranked #75 of 87 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹17.97 (as of 2026-11-13) |
|---|
| AUM | ₹825 Cr |
|---|
| Expense ratio | 1.98% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Dhananjay Tikariha |
|---|
| Exit load | 0.5% for redemption within 30 days |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −18.27% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 99.6% of NIFTY Pharma's upside and 101.0% of its downside.
Market cap allocation
| Large cap | 34.7% |
|---|
| Mid cap | 21.4% |
|---|
| Small cap | 43.8% |
|---|
Concentration
| Top 5 holdings | 37.6% |
|---|
| Top 10 holdings | 54.9% |
|---|
| Total holdings | 34 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 13.4%
- Divis Laboratories Ltd. — 10.2%
- ACUTAAS CHEMICALS LIMITED — 4.9%
- Molbio Diagnostics Limited — 4.7%
- Torrent Pharmaceuticals Ltd. — 4.3%
- Laurus Labs Limited — 4.2%
- Max Healthcare Institute Limited — 3.5%
- Gland Pharma Limited — 3.2%
- Apollo Hospitals Enterprises Ltd. — 3.2%
- Cipla Ltd. — 3.2%
Top sectors
- Pharma & Biotech — 69.6%
- Healthcare — 25.8%
- Chemicals — 3.6%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 35.7% | Q1 (Top) | #1 of 76 |
| 2025 | −7.3% | Q4 (Bottom) | #66 of 69 |
| 2024 | 39.5% | Q1 (Top) | #10 of 58 |